In 2019, at the age of 27, and after 3 years of follow-up without any symptoms or paroxysmal neurological events, the patient received a diagnosis of FHM secondary to CACNA1A and PKNPD gene mutations and started lacosamide (400 mg/d) as an add-on to topiramate (100 mg/d) with good seizure control and paroxetine (20 mg/d) and ketorolac for pain. Here, CACNA1A is linked to familial hemiplegic migraine.